Indeed, BcR signalling pathways are constitutively active in all CLL cases5, 6, and inhibitors of the downstream effectors Bruton's tyrosine kinase (Ibrutinib) or phosphoinositide 3-kinase δ (Idelalisib) show clinical efficacy7, 8. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.